Latest News & Features
Big Pharma
Pharmaceutical professionals should have a “wide-ranging” debate on how IP can be tailored in the face of “major changes” to the industry, including the possibility of “prolonged exclusivity” for certain medicines, according to a report. 6 June 2014
Americas
Pfizer and Mylan have agreed to settle litigation related to arthritis treatment Celebrex (celecoxib), Mylan announced today, June 2. 2 June 2014
Europe
London’s MedCity is working to boost collaboration between businesses in the area and invigorate the UK’s so-called ‘golden triangle’ life sciences cluster, with its three major centres in London, Oxford and Cambridge. LSIPR heard from Eliot Forster, who chairs MedCity, about the initiative. 30 May 2014
Americas
With the Federal Circuit relying on the precedent set by the Prometheus and Myriad decisions, Dolly the sheep has been summarily declared ineligible for patent protection. Nabeela Rasheed sums up the implications. 30 May 2014
Europe
London-based imaging company Imanova develops ‘imaging biomarkers’ to support the business of drug discovery, and takes a novel approach to protecting its innovations. LSIPR spoke to chief executive Kevin Cox about the company’s strategy. 30 May 2014
Americas
The new examination guidelines do not carry the weight of law, and it is not likely that their more extreme aspects will withstand judicial scrutiny, but practitioners need to keep tabs on court decisions, says Courtenay C. Brinckerhoff. 30 May 2014
Big Pharma
A pharmaceutical company in Turkey has run into trouble after attempting to register the Turkish word for ‘pharmacist’ as a trademark. 29 May 2014
Big Pharma
Teva has successfully defended a patent for its multiple sclerosis drug Copaxone (glatiramer acetate) in Europe. 28 May 2014
Biotechnology
Justice Colin Birss has refused Roche’s biotechnology subsidiary Genentech the permission to appeal against an English High Court decision in which two patents covering its blockbuster breast cancer drug, Herceptin (trastuzumab), were revoked. 27 May 2014
Americas
US-based drug company Acura and Novartis’s generic arm Sandoz have settled their patent infringement dispute related to an abuse-deterrent formulation of the painkiller Aversion (oxycodone). 23 May 2014